Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D Δr2-μMRA

Angiogenesis

Volumn 16, Issue 4, 2013, Pages 785-793

  Lin, Chien Yuan ^a,b   Siow, Tiing Yee ^a,b,c   Lin, Ming Huang ^a,b   Hsu, Yi Hua ^a,b   Tung, Yu Yin ^a,b   Jang, Taichang ^d   Recht, Lawrence ^d   Chang, Chen ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3D R2 MRA; Angiogenesis; Anti VEGF; Glioma; Vascular imaging

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY B20 4.1.1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; GLIOMA; MAGNETIC RESONANCE ANGIOGRAPHY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

RODENTIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; CORPUS STRIATUM; ETHYLNITROSOUREA; FEMALE; GLIOMA; IMAGING, THREE-DIMENSIONAL; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE ANGIOGRAPHY; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884814485     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9355-8     Document Type: Article

References (44)

1. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-6266. doi: 10.1200/JCO.2009.23.5622
2. Engstrom PF (2008) Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 28(11 Pt 2):18S-22S. doi: 10.1592/phco.28.11-supp.18S
3. Bellmunt J, Calvo E, Castellano D, Climent MA, Esteban E, Garcia del Muro X, Gonzalez-Larriba JL, Maroto P, Trigo JM (2009) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 63(Suppl 1):S1-S13. doi: 10.1007/s00280-009- 0955-3
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253-1259. doi: 10.1158/1078-0432.CCR-06-2309
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722-4729. doi: 10.1200/JCO.2007.12.2440
6. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66(8):1258-1260. doi: 10.1212/01.wnl.0000208958.29600.87
7. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1):83-95. doi: 10.1016/j.ccr.2006.11.021
8. Tateishi U, Kusumoto M, Nishihara H, Nagashima K, Morikawa T, Moriyama N (2002) Contrast-enhanced dynamic computed tomography for the evaluation of tumor angiogenesis in patients with lung carcinoma. Cancer 95(4):835-842. doi: 10.1002/cncr.10730
9. Raatschen HJ, Fu Y, Brasch RC, Pietsch H, Shames DM, Yeh BM (2009) In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol 44(5):265-270. doi: 10.1097/RLI.0b013e31819f1b60
10. Vakoc BJ, Lanning RM, Tyrrell JA, Padera TP, Bartlett LA, Stylianopoulos T, Munn LL, Tearney GJ, Fukumura D, Jain RK, Bouma BE (2009) Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med 15(10):1219-1223. doi: 10.1038/nm.1971
11. van Vliet M, van Dijke CF, Wielopolski PA, ten Hagen TL, Veenland JF, Preda A, Loeve AJ, Eggermont AM, Krestin GP (2005) MR angiography of tumor-related vasculature: from the clinic to the micro-environment. Radiographics 25(Suppl 1):S85-S97; discussion S97-S88. doi: 10.1148/rg. 25si055512
12. Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, Barbier EL (2008) Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 21(10):1043-1056. doi: 10.1002/nbm.1278
13. Lemasson B, Valable S, Farion R, Krainik A, Remy C, Barbier EL (2012) In vivo imaging of vessel diameter, size, and density: a comparative study between MRI and histology. Magn Reson Med. doi: 10.1002/mrm.24218
14. Peng SL, Chen CF, Liu HL, Lui CC, Huang YJ, Lee TH, Chang CC, Wang FN (2012) Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy. NMR Biomed. doi: 10.1002/nbm.2882
15. Coenegrachts K, Bols A, Haspeslagh M, Rigauts H (2012) Prediction and monitoring of treatment effect using T1-weighted dynamic contrast-enhanced magnetic resonance imaging in colorectal liver metastases: potential of whole tumour ROI and selective ROI analysis. Eur J Radiol. doi: 10.1016/j.ejrad.2012. 07.022
16. Shih TT, Hou HA, Liu CY, Chen BB, Tang JL, Chen HY, Wei SY, Yao M, Huang SY, Chou WC, Hsu SC, Tsay W, Yu CW, Hsu CY, Tien HF, Yang PC (2009) Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 113(14):3161-3167. doi: 10.1182/blood-2008-08-173104
17. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG (2005) Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol 12(10):1232-1240. doi: 10.1016/j.acra.2005.05.027
18. Nishimura S, Hirai T, Shigematsu Y, Kitajima M, Morioka M, Kai Y, Minoda R, Uetani H, Murakami R, Yamashita Y (2012) Evaluation of brain and head and neck tumors with 4D contrast-enhanced MR angiography at 3T. AJNR Am J Neuroradiol 33(3):445-448. doi: 10.3174/ajnr.A2819
19. Zou Z, Ma L, Cheng L, Cai Y, Meng X (2008) Time-resolved contrast-enhanced MR angiography of intracranial lesions. J Magn Reson Imaging (JMRI) 27(4):692-699. doi: 10.1002/jmri.21303
20. Pipe JG (2001) Limits of time-of-flight magnetic resonance angiography. Top Magn Reson Imaging (TMRI) 12(3):163-174
21. Lin CY, Lin MH, Cheung WM, Lin TN, Chen JH, Chang C (2009) In vivo cerebromicrovasculatural visualization using 3D DeltaR2-based microscopy of magnetic resonance angiography (3DDeltaR2-mMRA). NeuroImage 45(3):824-831. doi: 10.1016/j.neuroimage.2008.12.030
22. Jang T, Litofsky NS, Smith TW, Ross AH, Recht LD (2004) Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis. Neurobiol Dis 15(3):544-552. doi: 10.1016/j.nbd.2003.11.016
23. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G (2004) High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol 340(5):1073-1093. doi: 10.1016/j.jmb.2004.05.051
24. Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C (2006) Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 281(10):6625-6631. doi: 10.1074/jbc.M507783200
25. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2):951-961. doi: 10.1074/jbc.M508199200
26. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, Plowman GD (2010) Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 16(15):3887-3900. doi: 10.1158/1078-0432.CCR-09-3100
27. Wu EX, Wong KK, Andrassy M, Tang H (2003) High-resolution in vivo CBV mapping with MRI in wild-type mice. Magn Reson Med 49(4):765-770. doi: 10.1002/mrm.10425
28. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. Am J Neuroradiol (AJNR) 25(5):746-755
29. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol (AJNR) 24(10):1989-1998
30. Shin JH, Lee HK, Kwun BD, Kim JS, Kang W, Choi CG, Suh DC (2002) Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol (AJR) 179(3):783-789
31. Ludemann L, Grieger W, Wurm R, Budzisch M, Hamm B, Zimmer C (2001) Comparison of dynamic contrast-enhanced MRI with WHO tumor grading for gliomas. Eur Radiol 11(7):1231-1241
32. Siegal T, Rubinstein R, Tzuk-Shina T, Gomori JM (1997) Utility of relative cerebral blood volume mapping derived from perfusion magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 86(1):22-27. doi: 10.3171/jns.1997.86.1.0022
33. Sugahara T, Korogi Y, Tomiguchi S, Shigematsu Y, Ikushima I, Kira T, Liang L, Ushio Y, Takahashi M (2000) Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. Am J Neuroradiol (AJNR) 21(5):901-909
34. Cha S, Knopp EA, Johnson G, Litt A, Glass J, Gruber ML, Lu S, Zagzag D (2000) Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. Am J Neuroradiol (AJNR) 21(5):881-890
35. Akella NS, Twieg DB, Mikkelsen T, Hochberg FH, Grossman S, Cloud GA, Nabors LB (2004) Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging (JMRI) 20(6):913-922. doi: 10.1002/jmri.20202
36. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58-62. doi: 10.1126/science.1104819
37. Constable RT, Anderson AW, Zhong J, Gore JC (1992) Factors influencing contrast in fast spin-echo MR imaging. Magn Reson Imaging 10(4):497-511
38. Constable RT, Gore JC (1992) The loss of small objects in variable TE imaging: implications for FSE, RARE, and EPI. Magn Reson Med 28(1):9-24
39. Busse RF, Hariharan H, Vu A, Brittain JH (2006) Fast spin echo sequences with very long echo trains: design of variable refocusing flip angle schedules and generation of clinical T2 contrast. Magn Reson Med 55(5):1030-1037. doi: 10.1002/mrm.20863
40. Lebel RM, Wilman AH (2009) Time-efficient fast spin echo imaging at 4.7 T with low refocusing angles. Magn Reson Med 62(1):96-105. doi: 10.1002/mrm.21999
41. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM (1995) MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 34(4):555-566
42. Buschmann I, Schaper W (1999) Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol Sci 14:121-125
43. Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W (2006) Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 10(1):45-55
44. Jang T, Sathy B, Hsu YH, Merchant M, Recht B, Chang C, Recht L (2008) A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection. J Neurosurg 108(4):782-790. doi: 10.3171/JNS/2008/108/4/0782